Boston Scientific's FARAPULSE PFA System Receives FDA Approval for Expanded Indication in Persistent Atrial Fibrillation, Challenging Medtronic's Market Dominance
Medtronic
Medical Device Manufacturer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Heart Future
Recently,Boston Scientific(NYSE: BSX) announced itsFARAPULSE Pulsed Field Ablation (PFA) SystemHas received approval from the U.S. Food and Drug Administration (FDA) for expanded indications. This approval marks the official use of the FARAPULSE system for treatment.Drug-refractory, symptomatic persistent atrial fibrillationPatient.
Previously, onlyMedtronic's PFA products (Sphere-9 and PulseSelect)Can be used for treatmentPersistent Atrial Fibrillation, the recent FDA approval of Boston Scientific's FARAPULSE system successfully broke Medtronic's monopoly.
Previously, the FARAPULSE system could be used to treat through pulmonary vein electrical isolation.Drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation, is a brand-new solution beyond traditional thermal ablation therapy, relying on non-thermal electric fields for selective ablation of cardiac tissue, avoiding damage to surrounding structures.
AsThe world's first commercializedPFAProduct, Boston Scientific'sFARAPULSESystemIn2021Year1Month Obtained EUCECertification, followed by2024Year1Month,7Month and9Respectively obtained in the United States in ...FDA, ChinaNMPAAnd JapanPDMAMarketing Authorization.With the help ofThe continuous growth of the FARAPULSE system in global core markets has driven rapid growth in the company’s electrophysiology business revenue. Meanwhile, the company keeps iterating its products, and its next-generation catheter, FARAWAVE NAV, which features 3D mapping functionality, received FDA registration certification in the United States in October 2024.
This timeFDAUpdatedFARAWAVEAndFARAWAVE NAVThis2PaymentPFAInstructions for Use of the CatheterClarify its role inPersistent Atrial FibrillationTreatmentApplicability in。
Boston ScientificAlsoIndicates that in the coming monthsAlsoWill seek certification for corresponding label extensions in markets such as the EU, Japan, and China.
Chief Medical Officer of Boston Scientific's Atrial Fibrillation SolutionsBrad SuttonRepresentation："With solid clinical evidence and global market experience, this advancement represents an important step forward in driving the field of atrial fibrillation treatment. We look forward to exploring the system's application in repeat ablations and in patients with more complex arrhythmias through further clinical studies, as these patients still largely rely on thermal ablation methods."
# Boston Scientific Star ProductsFARAPULSESystem
As the most researched and utilized globallyPFASystem, Boston ScientificFARAPULSE The system has treated more than710,000 patients.
2025Year2Month5On the day, Boston Scientific announced2024Q4 and Full-Year Performance. Among them,Electrophysiology Business Q4 Sales6.49Billion US dollars, with total annual sales of19Billion US dollars, respectively increasing by nearly171%And138%。
The financial report stated that in2024Obtained at the beginning of the yearFDA After approval,FARAPULSEPulse Field Ablation System2024Sales at the end of the yearExceed10Billion US dollars. The company's leadership had previouslyFARAPULSE SystemDescribed as the most transformative product in Boston Scientific's history. Since its commercial launch, it has driven the growth of electrophysiology sales, including2024 Year-on-year growth in the first quarter70%, the second quarter125% And the third quarter177%。
Chairman and CEO of Boston ScientificCEO Mike MahoneySay,"2024The year was one of the best-performing years in Boco's history, thanks to our innovative product portfolio.FARAPULSEThe system's launch, along with clinical and commercial breakthroughs across businesses and regions. We have laid a strong foundation for growth and will continue to transform the lives of millions of patients worldwide."
FARAPULSESystem Composition
FARAPULSEThe system consists ofFARAWAVESingle-Use Cardiac Pulsed Field Ablation Catheter、FARASTARPulsed Electric Field Ablation SystemAndFARADRIVEDisposable Adjustable Bend Catheter SheathComposition.
FARADRIVE：Is a13FrA deflectable sheath with a steerable distal end can betterFARAWAVENavigate to the vestibules of various pulmonary veins。
FARAWAVE：It is a diameter12FrThe ablation catheter, whose distal end adopts a uniquePetal-shapedDesign, with a total of5"petals," each "petal" is equipped with4ElectrodeThe slider button on the handle can be used to control whether the distal end is in the "bud" or "full bloom" state. When5Each "petal" fully opens to form a flat petal shape. If partially expanded, it forms a three-dimensional basket shape. The basket diameter can be adjusted via catheter expansion and contraction.FARAWAVEThere is2Model Specifications（FARAWAVEAndFARAWAVE NAV），TheyThe biggest difference lies inMaximum diameter when the "flower" is in full bloom，The maximum diameter of this product is respectively31mmAnd35mm。
FARASTAR：Using bipolar and biphasic waveforms as well as proprietary pulses. The interface is simple to operate, just through3A single button can achieve pulmonary vein vestibule isolation.
Innovative Advantages
Multi-level Pulsed Electric Field Ablation:Possess1800V、1900V、2000VThree voltage parameter options, high tissue selectivity, reduced damage to adjacent tissues, and rapid formation of durable ablation lesions.
Unique“Petal”Structural Catheter:FARAWAVEThe petal design of the catheter can be adjusted to a basket shape or petal shape, adapting to different pulmonary vein morphologies, improving electrode contact with myocardial tissue, and enhancing surgical efficiency.
Standardized Ablation Procedure:Using a combination of basket-shaped and petal-shaped ablation with a rotating catheter to improve surgical fluidity and efficiency.。
Shorter learning curve:The interface is easy to operate, with a stable catheter tip designed for guidewire guidance. Efficient energy delivery reduces operational difficulty and shortens the doctor's learning curve.
# Relevant Clinical Data
ADVANTAGE AFClinical Trial
This FDAApproval based on the company's previously announcedADVANTAGE AFClinical trial data. Boston Scientific2025Year4Monthly Sharing of the Research Results, and predict thatThis yearObtained in the second half of the yearFDAApproval, now thisPrediction Successfully Achieved。
The approval of this expanded indication was obtainedADVANTAGE AFTest1Supported by the results of annual follow-up.
ADVANTAGE AFThe trial is a prospective, multi-center, single-arm trial conducted globally.43Central Inclusion260Example subjects, the ablation strategy received by all patients wasPulmonary Vein Isolation Combined with Posterior Wall Ablation。
The study design includes a one-year follow-up assessment, conducted postoperatively.6Months and12Months were carried out separately24HourHolterElectrocardiogram examination, and record the recurrence of atrial fibrillation through remote electrocardiographic monitoring twice a month and symptom-driven monitoring.
The primary safety endpoint isPresumed Incidence of Ablation-Related Adverse Events。
The primary efficacy endpoint includes the following composite metrics:Immediate success of ablation, no atrial arrhythmia within one year after the postoperative blanking period (>30seconds) recurrence, without the need for repeat ablation, cardioversion, or escalation of antiarrhythmic drug therapy.
1Annual follow-up results showed:
The incidence of the primary safety endpoint was2.3%, without serious complications such as cardiac tamponade, stroke, pulmonary vein stenosis, or esophageal fistula.
FARAPULSEReached its primary effectiveness endpoint,63.5%The subjects did not experience atrial fibrillation-related events or atrial fibrillation interventions.
85.3%Patients in1No recurrence of symptomatic atrial fibrillation within the year; efficacy varies depending on the operator's experience, and if the operator is highly experienced, this rate increases to91.8%。
▲Efficacy Endpoint
ADVENTResearch
12Positive results confirmed after several months.PFAThe Efficacy and Safety of the System in Treating Paroxysmal Atrial Fibrillation.
PFAThe immediate success rate of group pulmonary vein electrical isolation is99.6%, compared with the thermal ablation group99.8%Similar.
12During the follow-up months,PFAThe success rate of single surgery without oral antiarrhythmic medication is73.3%, Thermal Ablation Group is71.3%。
PFAIncidence of Group Adverse Events2.1%, Thermal Ablation Group1.5%, both are relatively low.
PFAThe group ablation time was significantly shorter than that of the thermal ablation group (29.2Minutevs 50.0Minutes).
AVANT GUARDClinical Trial
2023Year12Launch in Month, Evaluate FARAPULSESafety and Efficacy of the System as a First-Line Treatment for Persistent Atrial Fibrillation, Compared to...System and the therapeutic effects of antiarrhythmic drugs.
NAVIGATE-PFResearch
2024Year4Launch in Month, EvaluationFARAWAVE NAVVisualization and positioning functions of the catheter.FARAWAVE NAVThe catheter adds magnetic positioning function, enabling precise cardiac modeling, mapping, and ablation therapy.
ReMATCH IDEClinical Trial
In addition,Boco is also correctInAdvanceReMATCH IDEClinical trials are planned to be conducted in the United States and Asia.40Approximately recruited by the center375Number of patients.
This study will evaluateFARAWAVEThe Safety and Efficacy of Catheter in Pulmonary Vein Isolation and Posterior Wall Ablation, Mainly for Those Who Have UndergonePFAPatients with persistent atrial fibrillation who have undergone radiofrequency or cryoablation treatment but experienced recurrence of the condition.
The study will also exploreFARAPOINTCatheter Assistance in Ablation of the Tricuspid Isthmus and Mitral IsthmusTherapeutic Effect。
# Break Medtronic's Monopoly
In thisFARAPULSEBefore the system was approved by the FDA for a new indication, onlyMedtronic's PFA ProductSphere-9AndPulseSelect SystemCan be used to treat persistent atrial fibrillation.
PulseSelectSystem
PulseSelectSystem at2023Year obtainedFDAAndCEApproval,2024Year obtainedNMPAApproval, at that timeThe only one applicable to both paroxysmal atrial fibrillation and persistent atrial fibrillationTreatmentThePFAProduct。
Wide indications are suitable for MedtronicPulseSelectThe biggest advantage of the product, which also gives Medtronic an edge inPFAHas a natural advantage in the market.
PulseSelectIt is a new technology that utilizes pulsed electric fields to treat atrial fibrillation, delivering bipolar, biphasic pulsed electric fields via a circular multi-electrode array catheter.
PulseSelectConsists of 5 parts:Steerable Multi-Electrode Circular Ablation Catheter,PFAHost,ECG-Gated(ECG),Tableside control、10Fr Sheath。
PulseSelectThe steerable multi-electrode circular ablation catheter adopts a proprietary biphasic waveform, a unique built-in guidewire, and20°Forward-leaning design, capable of supporting the operability, reliability, and safety of the surgery.
Product Advantages
Safety：Compared with traditional ablation methods such as radiofrequency ablation or cryoablation,PulseSelectUsing non-thermal ablation methods, prioritize targeting cardiac tissue and selectively focus on myocardial cells to avoid unnecessary damage to surrounding tissues, thereby preventing complications associated with traditional ablation methods.
Efficient：HandThe duration of the device staying in the left ventricle during the procedure should not exceed50Minutes, excluding20Minutes of prescribed waiting period, average total energy delivery time is30Seconds to isolate all veins.
Clinical Data
PulseSelectThe system's safety, effectiveness, and efficiency have beenPULSED AFResearchThe study shows with the supportParoxysmal and Persistent Atrial FibrillationPatient Safety Incident Rate0.7%, with a clinical success rate of80%。
PULSED AFIs a global9A paired-arm, prospective, non-randomized study conducted in China aimed to evaluatePulseSelectSystemic Treatment of ParoxysmalOr PersistentSafety and efficacy in patients with atrial fibrillation. The study population includes...I Class orIII Antiarrhythmic drugsPatients with ineffective recurrent symptomatic paroxysmal and persistent atrial fibrillationSubjects. Experimental enrollment300Number of patients,96% (287) of patients completed12 Months of follow-up.
Safety：All atrial fibrillation to dateAblationIDEThe incidence of safety events in the trial was0.7%, is currently submitted toFDAThePFAClinical Trials and OthersPFAThe lowest in clinical studies; no esophageal events, phrenic nerve injury, or pulmonary vein observed.Stenosis or coronary artery spasm.
Effectiveness：Effective in both paroxysmal and persistent patients, for paroxysmal and persistent atrial fibrillationGroup, exceeded the predetermined performance targets>50%And>40%, the success rate of clinical surgeries has reached80%The above.2024Year9Month, publish newPulseSelectClinical research data, including patients with paroxysmal and persistent atrial fibrillation, showed that: two months after the operation, re-mapping results indicated,98%The pulmonary veins were persistently isolated,96%All veins of the patient were isolated.
Sphere-9Ablation Catheter
Except forPulseSelectOutside the system, Medtronic also has oneSphere-9The ablation catheter was also2024Year10Month approved for the treatment of persistent atrial fibrillation, this is an ablation catheter capable of delivering both radiofrequency energy and electrical pulse energy.
Sphere-9Is a7.5FrBidirectional steerable catheter with expandable conductive lattice electrode, inserted into the sheath in a folded form, but once inside the heart, the lattice expands to a diameter of9mmThe spherical structure. The lattice contains9A Microelectrode/Temperature Sensor (Diameter0.7mm), evenly distributed on its surface.
GCC2025
Full-spectrum Cardiovascular Device Solutions
SIYU Annual Activity Review:
The First Global Ophthalmology Conference The First Global Orthopedics Conference
The First Global Cardiovascular Conference The First Global Medical Aesthetics Technology Conference
Coming Soon:
July 17, 2025, The 2nd Global Medical Technology Conference
September 3-5, 2025, The 3rd Global Surgical Robotics Conference